Nestor Jaramillo: Absolutely. By being there with Qualimmune it’s an opportunity to talk about Aquadex, our current device and also started paving the way for our pediatric dedicated device.
Anthony Vendetti: That’s right. And then on the cost-cutting, I heard a 40% cut in monthly costs. Can you outline where that is coming from? And then when did the cuts start happening, what month?
Nestor Jaramillo: Yes, it started in March, March 1. And there are general expenses. We’re becoming more efficient in our headquarters in terms of the people that we need for our strategic growth initiatives. It also includes travel and travel and expenses and also includes salary cuts for the executive team and also the board fees.
Anthony Vendetti: I see. And it doesn’t — it sounds like obviously critical to your success is the clinical specialists and the sales. So that’s an area that has — is pretty much I wouldn’t say off limits, but hasn’t borne the brunt of the cost cutting at this point. Is that correct?
Nestor Jaramillo: Correct. Correct. We’re not touching the sales organization as they are key for continuing our growth in 2024.
Anthony Vendetti: Okay. And then lastly, some companies at this stage also employ independent distributors. Is there an opportunity to do that to help further spur sales going forward?
Nestor Jaramillo: Absolutely. Yes. We — that’s a very good point, Anthony. And we have 2 of them in key markets for us. One is in New York City and the other one is in Northern California. So we continue to look at opportunities to add more on this type of independent distributors.
Operator: Ladies and gentlemen, with that, we’ll be concluding today’s question-and-answer session. I’d like to turn the floor back over to Mr. Nestor Jaramillo, CEO, for closing remarks.
Nestor Jaramillo: Yes. Thank you, everyone, for participating. As I mentioned before, we’re very excited about the 2024. We continue to execute on our strategies redesigning our commercial strategy by adding DaVita and adding the collaboration with SeaStar. We’ll also continue our product development with our pediatric dedicated device and we continue to — committed to clinical research with our reverse heart failure trial. I want to thank all our stakeholders, including our employees, stockholders, medical staff, visions and health care workers without your help, we will not be able to achieve the transformation in the lives of patients suffering from fluid overload. Thank you.
Operator: Ladies and gentlemen, with that, we’ll conclude today’s conference call and presentation, we thank you for joining. You may now disconnect your lines.
